文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

新型冠状病毒肺炎与心血管疾病:从基础机制到临床展望。

COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives.

机构信息

Stanford Cardiovascular Institute, Stanford, CA, USA.

Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA.

出版信息

Nat Rev Cardiol. 2020 Sep;17(9):543-558. doi: 10.1038/s41569-020-0413-9. Epub 2020 Jul 20.


DOI:10.1038/s41569-020-0413-9
PMID:32690910
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7370876/
Abstract

Coronavirus disease 2019 (COVID-19), caused by a strain of coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic that has affected the lives of billions of individuals. Extensive studies have revealed that SARS-CoV-2 shares many biological features with SARS-CoV, the zoonotic virus that caused the 2002 outbreak of severe acute respiratory syndrome, including the system of cell entry, which is triggered by binding of the viral spike protein to angiotensin-converting enzyme 2. Clinical studies have also reported an association between COVID-19 and cardiovascular disease. Pre-existing cardiovascular disease seems to be linked with worse outcomes and increased risk of death in patients with COVID-19, whereas COVID-19 itself can also induce myocardial injury, arrhythmia, acute coronary syndrome and venous thromboembolism. Potential drug-disease interactions affecting patients with COVID-19 and comorbid cardiovascular diseases are also becoming a serious concern. In this Review, we summarize the current understanding of COVID-19 from basic mechanisms to clinical perspectives, focusing on the interaction between COVID-19 and the cardiovascular system. By combining our knowledge of the biological features of the virus with clinical findings, we can improve our understanding of the potential mechanisms underlying COVID-19, paving the way towards the development of preventative and therapeutic solutions.

摘要

新型冠状病毒病(COVID-19)是由一种称为严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)的冠状病毒引起的,已成为影响数十亿人生活的全球大流行。广泛的研究表明,SARS-CoV-2 与 SARS-CoV 有许多生物学特征,SARS-CoV 是导致 2002 年严重急性呼吸系统综合征爆发的人畜共患病病毒,包括细胞进入系统,该系统由病毒刺突蛋白与血管紧张素转换酶 2 的结合触发。临床研究还报告了 COVID-19 与心血管疾病之间的关联。先前存在的心血管疾病似乎与 COVID-19 患者的预后较差和死亡风险增加有关,而 COVID-19 本身也可引起心肌损伤、心律失常、急性冠状动脉综合征和静脉血栓栓塞症。影响 COVID-19 合并心血管疾病患者的潜在药物疾病相互作用也成为一个严重的问题。在这篇综述中,我们从基础机制到临床观点总结了对 COVID-19 的现有认识,重点关注 COVID-19 与心血管系统的相互作用。通过将我们对病毒生物学特征的了解与临床发现相结合,我们可以提高对 COVID-19 潜在机制的理解,为预防和治疗方法的发展铺平道路。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f5c/7370876/295e5430be4c/41569_2020_413_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f5c/7370876/544ee47b4361/41569_2020_413_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f5c/7370876/2852fb563cf0/41569_2020_413_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f5c/7370876/295e5430be4c/41569_2020_413_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f5c/7370876/544ee47b4361/41569_2020_413_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f5c/7370876/2852fb563cf0/41569_2020_413_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f5c/7370876/295e5430be4c/41569_2020_413_Fig3_HTML.jpg

相似文献

[1]
COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives.

Nat Rev Cardiol. 2020-7-20

[2]
Coronavirus disease 2019 and cardiovascular implications.

J Cardiovasc Med (Hagerstown). 2020-10

[3]
COVID-19: a conundrum to decipher.

Eur Rev Med Pharmacol Sci. 2020-5

[4]
ACE2 (Angiotensin-Converting Enzyme 2) in Cardiopulmonary Diseases: Ramifications for the Control of SARS-CoV-2.

Hypertension. 2020-8-12

[5]
Cardiovascular system is at higher risk of affecting by COVID-19.

Acta Biomed. 2020-9-7

[6]
Why are women better protected from COVID-19: Clues for men? Sex and COVID-19.

Int J Cardiol. 2020-9-15

[7]
Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty.

Curr Cardiol Rep. 2020-4-29

[8]
Coronavirus Disease 2019 and the Cerebrovascular-Cardiovascular Systems: What Do We Know So Far?

J Am Heart Assoc. 2020-5-12

[9]
Features of severe COVID-19: A systematic review and meta-analysis.

Eur J Clin Invest. 2020-8-29

[10]
Cardiovascular disease as a biomarker for an increased risk of COVID-19 infection and related poor prognosis.

Biomark Med. 2020-6

引用本文的文献

[1]
Global, regional and national burden of ischemic heart disease and its attributable risk factors from 1990 to 2021: a systematic analysis of the Global Burden of Disease study 2021.

BMC Cardiovasc Disord. 2025-8-21

[2]
COVID-19 in comorbid chronic diseased patients, pregnant and lactating women: pathophysiology, available drug treatment, and the most suitable protocol regimen in each group.

Inflammopharmacology. 2025-8-12

[3]
Therapeutic effect of cardiac rehabilitation on patients with long COVID combined with coronary heart disease: a retrospective study.

Front Cardiovasc Med. 2025-7-24

[4]
Top 10 drugs most frequently associated with adverse events of myocarditis and pericarditis.

Sci Rep. 2025-8-7

[5]
Co-infections during SARS-CoV-2 infection in hematologic patients and cell therapy recipients in the omicron era: a Spanish hematopoietic stem cell transplantation and cell therapy group study.

BMC Infect Dis. 2025-7-25

[6]
The Experience of SARS-CoV-2 in Patients with Benign Prostatic Hyperplasia: Is There Any Correlation between Them?

Maedica (Bucur). 2025-3

[7]
Pulmonary function and comparative SARS-CoV-2 RBD-specific IgG antibody response among the COVID-19 recovered group.

PLoS One. 2025-7-11

[8]
Risk Factors for Seeking Medical Care Following Nirmatrelvir-Ritonavir (Paxlovid) Treatment for COVID-19: "Symptom Rebound".

Viruses. 2025-5-29

[9]
SARS-CoV-2-Derived RNA Fragment Induces Myocardial Dysfunction via siRNA-like Suppression of Mitochondrial ATP Synthase.

Int J Mol Sci. 2025-6-4

[10]
2025 Expert Consensus Recommendations on Vaccinations in Adults with High Cardiovascular Risk and Cardiovascular Disease: A Report of the Task Force of the Taiwan Society of Cardiology and the Infectious Diseases Society of Taiwan.

Acta Cardiol Sin. 2025-5

本文引用的文献

[1]
The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) - China, 2020.

China CDC Wkly. 2020-2-21

[2]
Autopsy Findings and Venous Thromboembolism in Patients With COVID-19.

Ann Intern Med. 2020-12-15

[3]
Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19).

JAMA Cardiol. 2020-9-1

[4]
Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).

JAMA Cardiol. 2020-9-1

[5]
Human iPSC-Derived Cardiomyocytes Are Susceptible to SARS-CoV-2 Infection.

Cell Rep Med. 2020-7-21

[6]
Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients.

Cell Rep Med. 2020-6-23

[7]
Single-Cell RNA Expression Profiling of ACE2, the Receptor of SARS-CoV-2.

Am J Respir Crit Care Med. 2020-9-1

[8]
Myocardial edema in COVID-19 on cardiac MRI.

J Heart Lung Transplant. 2020-7

[9]
Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply.

N Engl J Med. 2020-9-3

[10]
COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles' heel conserved region to minimize probability of escape mutations and drug resistance.

Comput Biol Med. 2020-4-11

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索